VistaGen Therapeutics Inc (VTGN.OQ)
19 Jan 2018
Get access to over 18 million research reports from over 1,700 sources.
For several years, Reuters.com has provided analyst research reports for downloading. In an effort to streamline our website, analyst research will now be available from our dedicated page for Thomson Reuters On Demand, and the Reuters service will discontinue as of September 30, 2016.
Thomson Reuters On Demand provides over 18 million research reports from 1,700 sources.
Moreover, Thomson Reuters On Demand offers fast and cost-effective solutions that would allow you to retrieve information on:
- private equity
- third-party document and information retrieval
- and much, much more…
Click here to request a report and the team of expert analysts will get back to you shortly, to ensure you get the report you need.
|67||2011||President, Chief Scientific Officer, Director|
|54||2011||Chief Executive Officer, Director|
|62||2014||Chief Financial Officer, Vice President, Company Secretary|
|61||2016||Chief Medical Officer|
- BRIEF-Vistagen Therapeutics Receives FDA Fast Track Designation For Av-101 For Treatment Of Major Depressive Disorder
- BRIEF-Intracoastal Capital Llc Reports A 9.99 Pct Passive Stake In Vistagen Therapeutics As Of Dec 13
- BRIEF-Sabby Management LLC Reports A 9.15 Pct Passive Stake In Vistagen Therapeutics
- BRIEF-Vistagen Announces Pricing Of Underwritten Offering Of Common Stock And Warrants To Purchase Common Stock
- BRIEF-Vistagen Therapeutics posts Q2 loss of $0.53 per share